

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-90 (Cancelled).

91. (New) A method for metabolomically facilitating the diagnosis of a disease state of a subject, comprising:

obtaining a small molecule profile from a subject suspected of having and/or having a disease state; and

comparing the small molecule profile from the subject to a standard small molecule profile, thereby diagnosing the disease state.

92. (New) A method for metabolomically predicting whether a subject is predisposed to having a disease state, comprising:

obtaining a small molecule profile from the subject; and

comparing the small molecule profile from the subject to a standard small molecule profile, thereby predicting whether a subject is predisposed to having a disease state.

93. (New) A method for metabolomically predicting a subject's response to a therapeutic agent, comprising:

obtaining a small molecule profile from the subject;

comparing the small molecule profile of the subject to a known standard established for the therapeutic agent as an indication of whether the subject would benefit from treatment with the therapeutic agent, thereby predicting a subject's response to said therapeutic agent.

94. (New) A method for metabolomically monitoring the effectiveness of a therapeutic agent in clinical trials, comprising:

obtaining a small molecule profile from a subject in a clinical trial being treated with a therapeutic agent; and

monitoring changes in the small molecule profile of the subject as an indication of the effectiveness of the therapeutic agent in the subject, thereby monitoring the effectiveness of said therapeutic agent.

95. (New) The method of any one of claims 91-94, wherein said subject is a human.

96. (New) The method of any one of claims 91-94, wherein said subject is suffering or suspected of suffering from a disease state.

97. (New) The method of any one of claims 91-94, wherein said subject is suffering from an immunological, neurological, metabolic, oncological, viral, or a cardiovascular disorder.

98. (New) A method for generating a small molecule profile of a cellular compartment, comprising:

obtaining said cellular compartment from a source; and

analyzing said sample to determine the identity of the small molecules in said cellular compartment, thereby generating a small molecule profile of said cellular compartment.

99. (New) The method of claim 98, wherein said cellular compartment is a cell.

100. (New) The method of claim 98, wherein the method for analyzing the sample is selected from the group consisting of HPLC, TLC, electrochemical analysis, mass spectroscopy, refractive index spectroscopy (RI), Ultra-Violet spectroscopy (UV), fluorescent analysis, radiochemical analysis, Near-InfraRed spectroscopy (Near-IR), Nuclear Magnetic Resonance spectroscopy (NMR), and Light Scattering analysis (LS).

101. (New) The method of claim 100, wherein the method for analyzing the sample comprises two or more methods.

102. (New) The method of claim 98, wherein at least 50% of the small molecules of the cellular compartment are identified.

103. (New) The method of claim 102, wherein at least 70% of the small molecules of the cellular compartment are identified.

104. (New) The method of claim 98, wherein the source of the cellular compartment is suffering from a immunological, metabolic, cardiovascular, neurological, oncological, or viral disorder.

105. (New) The method of claim 98, wherein the source of the cellular compartments are selected from a subject's liver, heart, muscle, brain, nerve, stomach, pancreas, colon, bone, blood, or other tissue.

106. (New) A method for identifying disease relevant small molecules comprising:
obtaining a small molecule profile of a diseased cellular compartment; and
comparing the small molecule profile of said diseased cell to a standard small
molecule profile;
thereby, identifying the disease relevant small molecules in said diseased cellular
compartment.

107. (New) The method of claim 106, wherein said diseased cellular compartment is a cell.

108. (New) The method of claim 106, wherein said diseased cellular compartment is obtained
from a source suffering from an immunological, metabolic, cardiovascular, neurological,
oncological, or viral disorder.

109. (New) The method of claim 106, wherein said diseased cellular compartment is obtained
from a human.

110. (New) The disease relevant small molecules identified by the method described in claim
106.

111. (New) A method for identifying small molecules regulated, modulated, or associated
with a gene, comprising:
obtaining a small molecule profile of a cellular compartment from a genetically
modified source; and
comparing the small molecule profile to a standard small molecule profile, thus
identifying the small molecules regulated, modulated or associated with the gene.

112. (New) The method of claim 111, wherein said cellular compartment is a cell.

113. (New) The method of claim 111, wherein said genetic modification is an expression
vector.

114. (New) The method of claim 111, wherein said expression vector is a portion of the
human genome.

115. (New) The method of claim 111, wherein said expression vector is associated with a particular disease state.

116. (New) A method for identifying potential cell drug targets, comprising:
contacting a labeled disease relevant small molecule with cellular components;
and
identifying interactions between said cell components and the labeled disease-relevant small molecule, thus identifying potential cell drug targets.

117. (New) The method of claim 116, wherein said cellular components are a nucleic acid array.

118. (New) The method of claim 117, wherein said cellular components are a protein array.

119. (New) The cellular components identified by the method of claim 116.

120. (New) A library of small molecules of a cellular compartment of a cell comprising a searchable array of samples of small molecules from a cellular compartment.

121. (New) The library of claim 120, wherein said small molecules are isolated.

122. (New) The library of claim 120, wherein said cell is an animal cell.

123. (New) A method for determining whether small molecule profiles are from the same individual, comprising:
obtaining one or more samples from an individual;
determining the small molecule profiles of said samples;
obtaining a tissue sample from an unknown source;
determining the small molecule profile of the unknown source; and
comparing the small molecule profiles, thus determining whether the small molecule profiles are from the same individual.

124. (New) A pharmaceutical composition comprising a small molecule identified by the method of claim 91.

125. (New) A method for identifying small molecules relevant to a nervous system disorder, comprising:

obtaining a small molecule profile of a subject suffering from a nervous system disorder; and

comparing the small molecule profile to a standard small molecule profile; thereby, identifying the small molecules relevant to said nervous system disorder.

126. (New) The method of claim 125, wherein said nervous system disorder is a neurodegenerative disorder.

127. (New) The method of claim 125, wherein said nervous system disorder is neuropathy, Alzheimer disease, Parkinson's disease, amyotrophic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, acute disseminated encephalomyelitis, acute necrotizing hemorrhagic leukoencephalitis, dysmyelination disease, mitochondrial disease, migrainous disorder, bacterial infection, fungal infection, stroke, aging, dementia, or peripheral nervous system diseases.

128. (New) The method of claim 125, wherein said nervous system disorder is Huntington's disease.

129. (New) The method of claim 125, wherein said nervous system disorder is a mental disorder.

130. (New) The method of claim 129, wherein said mental disorder is schizophrenia or depression.

131. (New) The method of claim 125, wherein said subject is a human.

132. (New) The method of claim 125, wherein said small molecule profiles are obtained from said subject's blood, spinal fluid, serum, plasma, cells, tissue, or cellular organelles.

133. (New) The method of claim 125, wherein said small molecule profiles are obtained using one or more of the following: HPLC, TLC, electrochemical analysis, mass spectroscopy, refractive index spectroscopy (RI), Ultra-Violet spectroscopy (UV), fluorescent analysis, radiochemical analysis, Near-InfraRed spectroscopy (Near-IR), Nuclear Magnetic Resonance spectroscopy (NMR), and Light Scattering analysis (LS).

134. (New) A method for identifying small molecules relevant to a nervous system disorder, comprising:

obtaining a small molecule profile of a subject suffering from a nervous system disorder using one or more of the following technique, HPLC, electrochemical analysis, mass spectroscopy, and Nuclear Magnetic Resonance spectroscopy; and

comparing the small molecule profile to a standard small molecule profile; thereby, identifying the small molecules relevant to a nervous system disorder.

135. (New) A method for metabolomically facilitating the diagnosis of a nervous system disorder of a subject, comprising:

obtaining a small molecule profile from a subject suspected of having and/or having a nervous system disorder; and

comparing the small molecule profile from the subject to a standard small molecule profile, thereby diagnosing the nervous system disorder.

136. (New) The method of claim 134 or 135, wherein said nervous system disorder is neuropathy, Alzheimer disease, Parkinson's disease, amyotrophic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, acute disseminated encephalomyelitis, acute necrotizing hemorrhagic leukoencephalitis, dysmyelination disease, mitochondrial disease, migrainous disorder, bacterial infection, fungal infection, stroke, aging, dementia, peripheral nervous system diseases.

137. (New) The method of claim 134 or 135, wherein said nervous system disorder is Huntington's disease.

138. (New) The method of claim 134 or 135, wherein said nervous system disorder is a mental disorder.

139. (New) The method of claim 134 or 135, wherein said mental disorder is schizophrenia or depression.